Mar 04, 2025
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
Mar 03, 2025
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
Feb 24, 2025
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference
Feb 18, 2025
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Feb 05, 2025
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
Dec 19, 2024
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
Oct 30, 2024
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
Aug 07, 2024
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update
May 23, 2024
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 08, 2024
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
Apr 09, 2024
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Mar 13, 2024
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
Mar 05, 2024
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Mar 01, 2024
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
Jan 26, 2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
Jan 19, 2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium